Feb 7 (Reuters) – Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill. (Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: PROTESTERS MARCHING AGAINST MILANO CORTINA WINTER OLYMPICS RESENDING WITH CORRECTED SLATE SHOWS: MILAN,…
VIDEO SHOWS: HIGHLIGHTS OF MEN'S SNOWBOARD BIG AIR GOLD MEDAL EVENT/ WOMEN'S SKI JUMPING NORMAL…
By Nichola Groom Feb 6 (Reuters) - Tesla is hiring to support founder Elon Musk's…
ROME, Feb 7 (Reuters) - The Stellantis-backed Automotive Cells Company (ACC) told unions it had…
SEOUL, Feb 7 (Reuters) - South Korean cryptocurrency exchange Bithumb said on Saturday it had…
By Lewis Krauskopf NEW YORK, Feb 6 (Reuters) - An artificial intelligence-driven shakeout in the…